<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.medline.com/pages/community-impact-grant/">Medline Community Impact Grant Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Throughout our nation we are faced with many health inequities. Health outcomes for people living in vulnerable communities, and already disproportionately impacted by social determinants
of health (SDOH), are at an even greater health risk. SDOH are the economic and social conditions that influence individual and group differences in health status.
<b>Medline is committed to social determinants of health and through the Community Impact Grant Program we can promote good health for all people</b>. <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Medline is investing resources to help non-profit organizations address prevalent health challenges, stimulate health equity and improve population health in under resourced areas. We
will award results-focused grants that offer community- centered solutions and immediate impact. Through collaboration with community experts, we can provide essential resources, re-direct adverse outcomes and improve the well-being of people. This is, and
always will be, our ongoing commitment to communities. $25,000 awards.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 27, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: August 16.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-026.html">Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The National Cancer Institute (NCI) is publishing this Funding Opportunity Announcement (FOA) to request applications for the Program on the Origins of Gastroesophageal Cancers (R01).
This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular
level. The program will address the complex mechanisms and effectors that direct the proliferation and expansion of tumor-initiating cells and their progeny to initiate these cancers. The focus of the FOA is on gastric and gastroesophageal junction adenocarcinomas.
The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestations or neoplasia. This new program will be composed of up to six large R01 research grants
(to be supported by this FOA) and one Coordinating Center grant (to be supported by the companion FOA,
<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-027.html">RFA-CA-21-027</a>).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 8, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-21-006.html">CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets
that reduce acute effects of chemical threat agents that affect the lungs and eyes. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT)
NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 13, 2021; September 21, 2022; and September 20, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-069.html">Innovative Models for Delivering PrEP and STI Services to Stop HIV in the United States (R61 / R33 Clinical Trial
Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this FOA is to encourage and support the development of effective strategies for expanding the provision of HIV pre-exposure prophylaxis for people at increased risk but
currently lacking these services by leveraging existing sexually transmitted infection programs. Funding for the fourth and fifth years(s) will be dependent upon achieving negotiated Go/No-go criteria and milestones.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 13, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 30.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-029.html">HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules
and Biologics] (R61 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to
enable a future application for <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-015.html">
RFA-NS-21-015</a> HEAL Initiative: Team Research – for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are
expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research
team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication
and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; October 10, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-029.html">R61/R33 Basic Experimental Studies with Humans Required</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship
between sleep and substance use disorders (SUDs). Projects may explore the molecular, cellular, circuit and behavioral interactions between sleep and SUDs.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-016.html">R61/R33 Clinical Trials Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship
between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing
the risk for the development of SUDs and identifying new targets for prevention and therapeutics.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-016.html">Clinical Trials Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-029.html">Basic Experimental Studies with Humans Required</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship
between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing
the risk for the development of SUDs and identifying new targets for prevention and therapeutics. Projects may explore the molecular, cellular, circuit and behavioral interactions between sleep and SUDs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAS-21-245.html">Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) is to support applications to a new NIAMS initiative to encourage the skin research community to contribute to basic understanding of skin injuries
caused by chemical threats to the civilian population, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for countermeasure development.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-22-001.html">NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research
projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention
of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 20, 2021; June 20, 2022; February 22, 2023; October 18, 2023; June 20, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 / R01 Clinical Trial Required)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-240.html">R34</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs
(often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning
and design of a subsequent clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the
following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment,
retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials that test or determine
efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to
write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. Applications must propose to conduct a feasibility clinical trial. The subsequent larger trial should have the potential to
make a significant impact on public health.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-241.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological
therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can
be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across
sites; and/or demonstrate feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data
from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary
to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 20, 2021; February 18, 2022; June 20, 2022; October 19, 2022; February 21, 2023; June 20, 2023; October 20, 2023; February 20, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-046.html">Promoting Bunyavirales Basic Science Research (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to stimulate fundamental research of human disease-causing pathogens in the Bunyavirales order by supporting projects studying
vector competence, virology, pathogenesis, and immunity.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 22, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-019.html">High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimer’s Disease (R01 Clinical Trial Not
Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) will use the R01 funding mechanism to support discrete, specified, and circumscribed projects on novel molecular imaging approaches to establish
high-resolution mapping of biomolecules in brain cells and regions during the course of aging and Alzheimer’s disease (AD).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 28, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-018.html">Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis
Therapy and Drug Holiday (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits secondary analyses of existing datasets to provide evidence about appropriate strategies for long-term osteoporosis therapies, including
drug holidays, and to better understand their risks and benefits. This FOA encourages interdisciplinary studies utilizing innovative analytical approaches such as modeling studies or causal inference methods using data sources from large cohort studies, healthcare
systems including the Veterans Administration (VA), Centers for Medicare and Medicaid Services (CMS), FDA Sentinel network, Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), and other public, private, or commercial
datasets. The generalizability of study results is critical, and datasets should be representative of the population receiving osteoporosis therapy. Identification of disparities in outcomes according to demographic, ethnic, clinical, social, and other factors
are particularly encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 28, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-017.html">Role of Adaptive Immunity in Etiology of Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (R01 Clinical
Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) aims to explore the role of adaptive immunity in Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Specifically, the
FOA seeks an understanding of brain immune surveillance, the generation of CNS-directed immune responses in neurodegenerative disorders, and the functional role of adaptive immunity in AD/ADRD onset and progression.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 28, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-027.html" target="_blank">BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation
in the Nervous System (U01 Clinical Trials Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. The invention, proof-of-concept investigation, and optimization of new technologies through
iterative feedback from end users are key components of the BRAIN Initiative. This FOA seeks applications to optimize existing or emerging technologies through iterative testing with end users. The technologies and approaches should have potential to address
major challenges associated with recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling
in the central nervous system (CNS). These technologies and approaches should have previously demonstrated their transformative potential through initial proof-of-concept testing and are now ready for accelerated refinement. In conjunction, the manufacturing
techniques should be scalable towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience research.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Proposed technologies should be compatible with experiments in behaving animals, validated under
<i>in vivo</i> experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as
optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical
and physical sciences, engineering, computational modeling and statistical analysis.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 29, 2021 due date: October 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-026.html">BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01
Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies
and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in
the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region
and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological
experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple
approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 29, 2021 due date: October 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 / R01 Clinical Trial Required)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-241.html">R34</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-240.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to encourage research addressing major gaps identified in the United States Preventive Services Task Force recommendation
statement concerning interventions to prevent perinatal depression, with an emphasis on populations experiencing mental health disparities. The research scope for these FOAs includes<b>:
</b>1) refining and pilot testing strategies for identifying women at risk for perinatal depression; 2) developing and testing tools for selecting those most likely to benefit from preventive interventions; 3) refining and testing service-ready efficacious
preventive interventions that are of appropriate intensity/dose, and are scalable, such that they can be delivered with fidelity by setting providers; and, 4) optimizing and testing strategies that can be used to train providers and to support delivery of
evidence-based approaches with fidelity across diverse health care and community settings.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-017.html" target="_blank">PrEP for HIV Prevention among Substance Using Populations (R01 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NIDA is interested in research that addresses research gaps related to PrEP and its use among people who use drugs (PWUD), with the goals of improving PrEP uptake, adherence and implementation.
Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. More systematic data are needed regarding the impact of substance use
on PrEP management and adherence, as well as the best ways to deliver PrEP and integrate it with other services. Recent trials have demonstrated the efficacy of injectable Cabotegravir as PrEP, although no data exist for PWUD and there is a need to inform
the best practices for delivery and management of injectable PrEP among PWUD, as well as for oral PrEP. This RFA is restricted to projects conducted in the United States. Applications are encouraged that propose research in states and counties identified in
the US Government’s Ending the HIV Epidemic (EHE) initiative. Applications to work in locales that are not included in the EHE initiative must provide an epidemiologic justification for their inclusion in the research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 12, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-009.html">Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced
microglia and cerebral organoids generated from human derived induced pluripotent stem cell (iPSC) lines. Specific emphasis is on the comorbidity of HIV and neural stimulants, including methamphetamine, amphetamine, cocaine, and nicotine, studied at the single
cell and neural circuits levels.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 17, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-004.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-003.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements is to solicit research to better understand the epidemiology and biology of oral human papillomavirus (HPV) infection, its acquisition
and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. The FOAs intend to address broad knowledge gaps related to biological, immunogenetic,
clinical, and socio-behavioral factors and mechanisms for oral HPV co-infection and persistence in the oral cavity and oropharynx of HIV-seropositive individuals.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 18, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 4.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b><o:p></o:p></span></p>
</div>
</body>
</html>